Glucocorticoid Receptor-Deficient Foxp3+ Regulatory T Cells Fail to Control Experimental Inflammatory Bowel Disease
Open accessThe DOI matches its Crossref record; 8 of the 8 references it cites were found in a registry or an index.
Abstract
Activation of the immune system increases systemic adrenal-derived glucocorticoid (GC) levels which downregulate the immune response as part of a negative feedback loop. While CD4+ T cells are essential target cells affected by GC, it is not known whether these hormones exert their major effects on CD4+ helper T cells, CD4+Foxp3+ regulatory T cells (Treg cells), or both. Here, we generated mice with a specific deletion of the glucocorticoid receptor (GR) in Foxp3+ Treg cells. Remarkably, while basal Treg cell characteristics and in vitro suppression capacity were unchanged, Treg cells lacking the GR did not prevent the induction of inflammatory bowel disease in an in vivo mouse model. Under inflammatory conditions, GR-deficient Treg cells acquired Th1-like characteristics and expressed IFN-gamma, but not IL-17, and failed to inhibit pro-inflammatory CD4+ T cell expansion in situ. These findings reveal that the GR is critical for Foxp3+ Treg cell function and suggest that endogenous GC prevent Treg cell plasticity towards a Th1-like Treg cell phenotype in experimental colitis. When equally active in humans, a rationale is provided to develop GC-mimicking therapeutic strategies which specifically target Foxp3+ Treg cells for the treatment of inflammatory bowel disease.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Immune regulation by glucocorticoids
Cain, D. W., & Cidlowski, J. A. (2017) · Nature Reviews Immunology · doi:10.1038/nri.2017.1 · Cited by 1,846
Regulatory T Cell-Derived Interleukin-10 Limits Inflammation at Environmental Interfaces
Rubtsov, Y. P., Rasmussen, J. P., Chi, E. Y., Fontenot, J., Castelli, L., Ye, X., Treuting, P., Siewe, L., Roers, A., Henderson, W. R., et al. (2008) · Immunity · doi:10.1016/j.immuni.2008.02.017 · Cited by 1,586
Powrie, F., Leach, M. W., Mauze, S., Caddie, L. B., & Coffman, R. L. (1993) · International Immunology · doi:10.1093/intimm/5.11.1461 · Cited by 1,078
Genome-wide analysis of Foxp3 target genes in developing and mature regulatory T cells
Zheng, Y., Josefowicz, S. Z., Kas, A., Chu, T.-T., Gavin, M. A., & Rudensky, A. Y. (2007) · Nature · doi:10.1038/nature05563 · Cited by 835
Regulatory T cells in autoimmune disease
Dominguez-Villar, M., & Hafler, D. A. (2018) · Nature Immunology · doi:10.1038/s41590-018-0120-4 · Cited by 713 · cited 2×
“Some Treg cells may lose Foxp3 expression in autoimmune disease (“ex-Foxp3” cells), others, while maintaining Foxp3 expression, acquire a certain degree of plasticity which is illustrated by secretion of pro-inflammatory cytokines and reduced suppressive function (4).”
BackgroundIdentification of T helper type 1–like, Foxp3+ regulatory T cells in human autoimmune disease
Dominguez-Villar, M., Baecher-Allan, C. M., & Hafler, D. A. (2011) · Nature Medicine · doi:10.1038/nm.2389 · Cited by 526 · cited 1×
“Such Th1-like Treg cells producing IFN-gamma (but maintaining Foxp3 expression) have been reported to be present at an increased frequency in both mouse models (39) and patients with autoimmune diseases such as type 1 diabetes (40) or multiple sclerosis (41).”
BackgroundPlasticity of Human Regulatory T Cells in Healthy Subjects and Patients with Type 1 Diabetes
McClymont, S. A., Putnam, A. L., Lee, M. R., Esensten, J. H., Liu, W., Hulme, M. A., Hoffmüller, U., Baron, U., Olek, S., Bluestone, J. A., et al. (2011) · The Journal of Immunology · doi:10.4049/jimmunol.1003099 · Cited by 428 · cited 1×
“Such Th1-like Treg cells producing IFN-gamma (but maintaining Foxp3 expression) have been reported to be present at an increased frequency in both mouse models (39) and patients with autoimmune diseases such as type 1 diabetes (40) or multiple sclerosis (41).”
BackgroundLuther, C., Adamopoulou, E., Stoeckle, C., Brucklacher-Waldert, V., Rosenkranz, D., Stoltze, L., Lauer, S., Poeschel, S., Melms, A., & Tolosa, E. (2009) · The Journal of Immunology · doi:10.4049/jimmunol.0802046 · Cited by 93 · cited 1×
“Supporting the view that the GR enhances Treg cell function is the observation that GC treatment of patients suffering from myasthenia gravis or multiple sclerosis not only improved clinical disease symptoms but also enhanced Treg cell function (12, 49) and inhibitory cytokine production (12), as compared to untreated…”
Cited by
Intestinal epithelial cells: At the interface of the microbiota and mucosal immunity
Soderholm, A. T., & Pedicord, V. A. (2019) · Immunology · doi:10.1111/imm.13117 · Cited by 281
Control of immunity by glucocorticoids in health and disease
Shimba, A., & Ikuta, K. (2020) · Seminars in Immunopathology · doi:10.1007/s00281-020-00827-8 · Cited by 183
Obradovic, A., Ager, C., Turunen, M., Nirschl, T., Khosravi-Maharlooei, M., Iuga, A., Jackson, C. M., Yegnasubramanian, S., Tomassoni, L., Fernandez, E. C., et al. (2023) · Cancer Cell · doi:10.1016/j.ccell.2023.04.003 · Cited by 66
Shimba, A., Cui, G., Abe, S., Hirota, K., Miyauchi, E., Takami, D., Tani-ichi, S., Kato, R., Tajima, M., Kanahashi, T., et al. (2025) · Cell Reports · doi:10.1016/j.celrep.2025.116093 · Cited by 15
Metadata
- Authors
- Rocamora-Reverte, L., Tuzlak, S., von Raffay, L., Tisch, M., Fiegl, H., Drach, M., Reichardt, H. M., Villunger, A., Tischner, D., & Wiegers, G. J.
- Venue
- Frontiers in Immunology
- Publisher
- Frontiers Media SA
- Published
- 2019-03-18
- Volume
- 10
- Pages
- 472-472
- ISSN
- 1664-3224 (ISSN-L)
- OpenAlex
- W2921178159
- Cited by
- 43
- References
- 8
- FWCI
- 2.32
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.